View of Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program

Return to Article Details Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program Download Download PDF